12/05/2025
Now enrolling: the D2C7 + Anti-CD40 trial for patients with malignant glioma.
This study is testing whether a targeted immunotoxin (D2C7) combined with an immune- stimulating antibody (anti-CD40) can work together to kill tumor cells and activate the immune system. It’s a novel approach that aims to attack the tumor from both the inside and out.
To learn more about eligibility, visit https://clinicaltrials.gov/study/NCT05734560.